Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)

NCT05772169 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT05772169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05772169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)
Lead sponsor
Corcept Therapeutics
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2023
Completion date
December 18, 2024
Enrollment
1,113 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, hypercortisolism